We serve Chemical Name:Aniline phosphinate CAS:82395-88-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Aniline phosphinate
CAS.NO:82395-88-8
Synonyms:aniline,phosphenous acid
Molecular Formula:C6H10NO2P
Molecular Weight:159.12300
HS Code:2922499990
Physical and Chemical Properties:
Melting point:113-115ºC(lit.)
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:73.13000
Exact Mass:159.04500
LogP:1.50000
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 2811 6.1/PG 3
Packing Group:
Contact us for information like aniline,phosphenous acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,aniline,phosphenous acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,aniline,phosphenous acid Use and application,aniline,phosphenous acid technical grade,usp/ep/jp grade.
Related News: China’s pharmaceutical CMO market has recently maintained a growth rate of more than 10%. From the perspective of market structure, the average growth rate of clinical production is 9.5%, while the average growth rate of commercial production will reach 18.7%. Aniline phosphinate manufacturer China has asked the European Union for help in buying urgently needed medical supplies from its member countries, the China��s official Xinhua news agency said on Saturday. Aniline phosphinate supplier Our quality control staff then conducts analyses in the testing laboratory to examine whether the API manufactured is ultrapure. Aniline phosphinate vendor Our quality control staff then conducts analyses in the testing laboratory to examine whether the API manufactured is ultrapure. Aniline phosphinate factory Jo Soden, Co-managing Director of Retrogenix, said ��We look forward to working with Resonant to deconvolute the targets for their antibodies. Resonant��s innovative platform is delivering functional therapeutic candidates at rapid pace and we welcome the opportunity to identify the specific, biologically-relevant targets which will help progress these leads towards promising new therapies for patients with cancer.��
